Russia's public procurement of drugs significantly declining

The Russian segment of drug public procurements significantly declined this year, mainly as a result of a significant drop of purchases under various state programs, The Pharma Letter’s local correspondent reports.

According to data of Headway Company, in January-July 2023, drugs’ public procurements in Russia decreased by 18% year-on-year basis to 452.8 billion roubles ($4.67 billion), which still makes this segment very attractive for global drugmakers.

According to analysts, one of the reasons for the decline was due to a significant drop of state purchases under federal programs, including “14 high-cost nosologies” (14 VZN)  - a state program, which involves purchases the most expensive, original drugs.